Please join Ocular Therapeutix™ for its 2026 Investor Day. The Event will feature prominent retinal disease Key Opinion Leaders (KOLs) and presentations from senior Company leadership.

Key areas of focus include:
• Regulatory updates regarding NDA submission plan for AXPAXLI™ in wet AMD
• Detailed updates on SOL-R and SOL-X
• Registrational program update in diabetic retinopathy
• Overview of the planned commercialization strategy for AXPAXLI, if approved

A live question and answer session and cocktail reception will follow the formal presentations. Additional event information and logistics will be provided in advance.